Spruce Biosciences (SPRB) Expected to Announce Earnings on Monday

Spruce Biosciences (NASDAQ:SPRB) is expected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $0.67 million for the quarter.

Spruce Biosciences Stock Up 12.5%

NASDAQ:SPRB opened at $11.39 on Friday. The company’s 50-day simple moving average is $5.89 and its 200-day simple moving average is $14.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.36 and a current ratio of 5.36. Spruce Biosciences has a fifty-two week low of $0.06 and a fifty-two week high of $0.61. The stock has a market capitalization of $6.40 million, a P/E ratio of -12.12 and a beta of 2.43.

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada lowered their target price on shares of Spruce Biosciences from $112.50 to $37.50 and set a “sector perform” rating for the company in a research note on Wednesday, April 16th. Six analysts have rated the stock with a hold rating, According to MarketBeat, the company has an average rating of “Hold” and an average price target of $131.25.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.